DNER and acute myeloid leukemia: Thus, BET inhibitors have shown promising results in tumors that are dependent on these transcriptional programs including castration-resistant prostate cancer [105], breast cancer [106], non-small cell lung cancer, gastrointestinal cancers including colon cancer, gliomas, and several hematological malignancies such as acute myeloid leukemia [107], lymphoma, and multiple myeloma [108].